Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Rhea-AI Impact

(Very High)

Rhea-AI Sentiment

(Neutral)

Key Terms

u.s. patent regulatory

A U.S. patent is a government-granted right that gives its holder exclusive control over making, using, selling or importing a specific invention inside the United States for a limited time. Think of it like owning the only key to a locked box or a secret recipe for a product. For investors, patents can create a legal barrier against competitors, boost potential sales or licensing income, and therefore increase a company’s value — but they also require time and money to obtain and defend, and their protection ends when they expire.

clinical trials medical

Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.

intellectual property regulatory

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

neuroplastogenic medical

Neuroplastogenic describes a drug, molecule or treatment that actively promotes neuroplasticity — the brain’s ability to rewire itself by creating or strengthening connections between nerve cells. Think of it as encouraging a tangled garden path to be replanted and smoothed so signals travel more easily; for investors, neuroplastogenic activity can signal potential for lasting benefit in neurological or psychiatric disorders, larger market opportunity, and distinct regulatory and development risks.

small-molecule therapeutics medical

Small-molecule therapeutics are low-weight chemical drugs designed to enter cells and directly interact with specific proteins or pathways, like tiny keys that fit into biological locks to change how a cell works. They matter to investors because they often can be taken orally, manufactured at scale more cheaply than larger biologic drugs, and follow well-established regulatory paths, which influences development risk, time to market and production costs.

02/25/2026 - 08:00 AM

As a result of this action, there are no remaining challenges currently pending against Enveric’s patent

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the previously announced Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals (Gilgamesh) against Enveric’s issued U.S. Patent No. 12,138,276 (the ’276 patent) has been withdrawn. This action follows Enveric’s filing of a Request for Discretionary Denial of the petition. As a result of this action, there are no remaining challenges currently pending against Enveric’s patent.

Enveric’s ‘276 patent, entitled, “Halogenated psilocybin derivatives and methods of using," includes claims that appear relevant to the bretisilocin (GM-2505) molecule currently in clinical trials.

On August 12, 2025, Gilgamesh filed a PGR petition in the United States Patent and Trademark Office, Patent Trial and Appeal Board (PTAB) against Enveric’s ’276 patent. On August 25, 2025, AbbVie Inc. agreed to acquire bretisilocin from Gilgamesh in a definitive transaction valued at up to $1.2 billion (AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline). On November 7, Gilgamesh notified the PTAB that on October 17, 2025, the petitioner, Gilgamesh Pharmaceuticals, Inc., became a wholly owned subsidiary of Warka Intermediate LLC, which is in turn a wholly owned subsidiary of AbbVie Inc. In that filing, Gilgamesh identified Warka Intermediate LLC and AbbVie Inc. as real parties-in-interest in the proceeding.

On October 15, 2025, Enveric announced that it had hired intellectual property powerhouse Fish and Richardson P.C. to contest the PGR petition filed by Gilgamesh against Enveric’s ’276 patent. On October 24, 2025, Fish and Richardson filed a Request for Discretionary Denial of the PGR petition on behalf of Enveric.

On November 20, counsel for AbbVie filed a request to the USPTO asking to withdraw the petition Gilgamesh had filed. Enveric is pleased to announce that the PTAB granted the request, and the petition is now withdrawn.

“Enveric is gratified by this turn of events, which we believe demonstrates our willingness to fully defend the intellectual property that protects our valuable discoveries,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “The fact that the PGR petition was filed in the first place underscored the breadth of our intellectual property footprint in the field, embodied by the numerous discoveries pertaining to next-generation, small-molecule psychedelics and potential non-hallucinatory neuroplastogenic therapeutics targeting psychiatric and neurological disorders. We believe that our patent portfolio will continue to generate value for our shareholders and support our efforts towards developing novel therapeutics to benefit patients with mental health conditions.”

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT₂_A and 5-HT₁_B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.

For more information, please visit www.enveric.com.

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores," "schedules," "seeks," “sees,” "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.

A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.